1. Murakami M, Hayakawa M, Yanagihara T, et al. Proteinuria screening for children. Kidney Int Suppl. 2005;94:s23–s27.
2. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–39.
3. Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic. kidney disease. Nat Rev Nephrol. 2016;12(3):133–46.
4. Ashraf S, Gee HY, Woerner S, et al. COQ8B mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest. 2013;123(12):5179–89.
5. Rao J, Liu X, Mao J, et al. Genetic spectrum of renal disease for 1001 Chinese children based on a multicenter registration system. Clin Genet. 2019;96(5):402–10.
6. Quinzii C, Naini A, Salviati L, et al. A Mutation in Para-Hydroxybenzoate-Polyprenyl Transferase (COQ2) Causes Primary Coenzyme Q10 Deficiency. Am J Hum Genet. 2006;78(2):345–9.
7. López LC, Schuelke M, Quinzii,et al. Leigh Syndrome with Nephropathy and CoQ10 Deficiency Due to decaprenyl diphosphate synthase subunit 2 (PDSS2) Mutations. Am J Hum Genet. 2006;79(6):1125–9.
8. Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest. 2011;121(5):2013–24.
9. Korkmaz E, Lipska-Ziętkiewicz BS, Boyer O, et al. COQ8B-associated glomerulopathy causes adolescence-onset FSGS. J Am Soc Nephrol. 2016;27(1):63–8.
10. Atmaca M, Gulhan B, Korkmaz E, et al. Follow-up results of patients with COQ8B mutations and the efficacy of CoQ10 treatment. Pediatr Nephrol. 2017;32(8):1369–75.
11. Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;19(2):249–55.
12. Yip GW, Li AM, So HK, et al. Oscillometric 24-h ambulatory blood pressure reference values in Hong Kong Chinese children and adolescents. J Hypertens. 2014;32(3):606–19.
13. Flynn JT, Daniels SR, Hayman LL, et al. Update: ambulatory blood pressure monitoring in children and adolescents: a scientific statement from the American Heart Association. Hypertension. 2014;63(5):1116–35.
14. Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.
15. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–47.
16. Patrakka J, Ruotsalainen V, Reponen P, et al. Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the finnish type: role of nephrin. Transplantation. 2002;73(3):394–403.
17. Jungraithmayr TC, Hofer K, Cochat P, et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol. 2011;22(3):579–85.
18. Gillion V, Dahan K, Cosyns JP, et al. Genotype and Outcome After Kidney Transplantation in Alport Syndrome. Kidney Int Rep. 2018;3(3):652–60.
19. Mange KC. Cizman B, Joffe M. Feldman HI: Arterial hypertension and renal allograft survival. JAMA 283(5): 633 – 638.
20. Hamdani G, Nehus EJ, Hanevold CD, et al. Ambulatory Blood Pressure Control in Children and Young Adults After Kidney Transplantation. Am J Hypertens. 2017;30(10):1039–46.
21. Suláková T, Feber J. Should mean arterial pressure be included in the definition of ambulatory hypertension in children? Pediatr Nephrol. 2013;28(7):1105–12.
22. Tran MT, Mitchell TM, Kennedy DT, et al. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy. 2001;21(7):797–806.
23. Ho MJ, Li EC, Wright JM. Blood pressure lowering efficacy of coenzyme Q10 for primary hypertension. Cochrane Database Syst Rev. 2016;3:CD007435.